PMC:7696151 / 77847-78501 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2289","span":{"begin":292,"end":296},"obj":"Species"},{"id":"2290","span":{"begin":335,"end":338},"obj":"Chemical"},{"id":"2291","span":{"begin":388,"end":403},"obj":"Chemical"},{"id":"2292","span":{"begin":181,"end":187},"obj":"Disease"},{"id":"2293","span":{"begin":267,"end":283},"obj":"Disease"},{"id":"2294","span":{"begin":438,"end":443},"obj":"Disease"},{"id":"2295","span":{"begin":595,"end":601},"obj":"Disease"}],"attributes":[{"id":"A2289","pred":"tao:has_database_id","subj":"2289","obj":"Tax:10090"},{"id":"A2290","pred":"tao:has_database_id","subj":"2290","obj":"MESH:D006886"},{"id":"A2291","pred":"tao:has_database_id","subj":"2291","obj":"MESH:C017092"},{"id":"A2292","pred":"tao:has_database_id","subj":"2292","obj":"MESH:D009369"},{"id":"A2293","pred":"tao:has_database_id","subj":"2293","obj":"MESH:D001201"},{"id":"A2294","pred":"tao:has_database_id","subj":"2294","obj":"MESH:D009369"},{"id":"A2295","pred":"tao:has_database_id","subj":"2295","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Together with autophagy, glycolysis plays a pivotal role in satisfying the increased energetic demand. The dual targeting of the processes may provide a new therapeutic approach in cancer cells. Emonet, et al. [150] performed a randomized preclinical study on Earlic ascites hepatoma-bearing mice, showing that the coadministration of HCQ (60 mg/kg i.p.) and the antiglycolytic inhibitor 3-bromopyruvate possessed a synergistic effect on tumor growth inhibition. Moreover, this treatment is associated with an improvement of oxidative status in hepatic tissue, with a decrement in the number of cancer cells, without affecting the total cell count [151]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T169","span":{"begin":181,"end":187},"obj":"Phenotype"},{"id":"T170","span":{"begin":267,"end":274},"obj":"Phenotype"},{"id":"T171","span":{"begin":438,"end":443},"obj":"Phenotype"},{"id":"T172","span":{"begin":595,"end":601},"obj":"Phenotype"}],"attributes":[{"id":"A169","pred":"hp_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A170","pred":"hp_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/HP_0001541"},{"id":"A171","pred":"hp_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A172","pred":"hp_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Together with autophagy, glycolysis plays a pivotal role in satisfying the increased energetic demand. The dual targeting of the processes may provide a new therapeutic approach in cancer cells. Emonet, et al. [150] performed a randomized preclinical study on Earlic ascites hepatoma-bearing mice, showing that the coadministration of HCQ (60 mg/kg i.p.) and the antiglycolytic inhibitor 3-bromopyruvate possessed a synergistic effect on tumor growth inhibition. Moreover, this treatment is associated with an improvement of oxidative status in hepatic tissue, with a decrement in the number of cancer cells, without affecting the total cell count [151]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T499","span":{"begin":0,"end":102},"obj":"Sentence"},{"id":"T500","span":{"begin":103,"end":194},"obj":"Sentence"},{"id":"T501","span":{"begin":195,"end":462},"obj":"Sentence"},{"id":"T502","span":{"begin":463,"end":654},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Together with autophagy, glycolysis plays a pivotal role in satisfying the increased energetic demand. The dual targeting of the processes may provide a new therapeutic approach in cancer cells. Emonet, et al. [150] performed a randomized preclinical study on Earlic ascites hepatoma-bearing mice, showing that the coadministration of HCQ (60 mg/kg i.p.) and the antiglycolytic inhibitor 3-bromopyruvate possessed a synergistic effect on tumor growth inhibition. Moreover, this treatment is associated with an improvement of oxidative status in hepatic tissue, with a decrement in the number of cancer cells, without affecting the total cell count [151]."}